ClinicalTrials.gg
Not yet recruitingNCT07026292SLVA-PULLUpdated Jun 18, 2025

Supermicrosurgical Lymphaticovenous Anastomosis for Prevention of Upper Limb Lymphedema

An interventional study of Immediate Distal Lymphaticovenous Anastomosis (ID-LVA) in Breast Cancer-Related Lymphedema, Lymphedema and Breast Cancer Invasive, sponsored by Tianjin Medical University Cancer Institute and Hospital. Not yet recruiting. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-18.

Sponsored by Tianjin Medical University Cancer Institute and Hospital · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Study summary

Breast cancer-related lymphedema (BCRL) is one of the most common chronic complications following breast cancer treatment. This study enrolls breast cancer patients who are required to undergo axillary lymph node dissection and postoperative adjuvant radiotherapy. Based on patients' preferences, they will be assigned to receive either immediate distal lymphaticovenous anastomosis (ID-LVA) following axillary lymph node dissection (experimental group) or not (control group). The study aims to evaluate the safety and efficacy of ID-LVA in preventing breast cancer-related upper limb lymphedema.

02

Conditions studied

  • Breast Cancer-Related Lymphedema
  • Lymphedema
  • Breast Cancer Invasive

Keywords

  • Supermicrosurgical Lymphaticovenous Anastomosis
  • Lymphedema
  • Breast Cancer
  • Prevention
  • Immediate Distal Lymphaticovenous Anastomosis
03

In context

Breast Cancer Lymphedema

124 studies on the registry are indexed under Breast Cancer Lymphedema; 39 are open to participants now.

This study's planned enrollment of 120 is above the median of 48 across 97 interventional studies indexed under Breast Cancer Lymphedema.

Browse Breast Cancer Lymphedema studies →

Lead sponsor

Tianjin Medical University Cancer Institute and Hospital is the lead sponsor of 499 studies on the registry; 298 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age >=18 years;
  2. Female;
  3. confirmed invasive breast cancer;
  4. Unilateral breast cancer;
  5. Clinical stage T1-4 and N1-3 (post- therapy staging for patients receiving neoadjuvant treatment);
  6. No clinical or radiographic evidence of distant ;
  7. Scheduled to undergo axillary lymph node dissection with planned adjuvant radiotherapy;
  8. Willing and able to provide written .

Exclusion criteria

Exclusion Criteria:

  1. Currently participating in other clinical trials that, in the investigator's judgment, may affect upper limb lymphatic drainage.
  2. No definitive indication for axillary lymph node dissection or radiotherapy after neoadjuvant therapy.
  3. Pregnant or lactating women.
  4. Patients undergoing concurrent autologous tissue flap breast reconstruction or chest wall repair.
  5. Upper limb deformities, prior upper limb trauma, or surgical history that, in the investigator's assessment, may compromise lymphatic drainage.
  6. Pre-existing upper limb lymphedema at baseline.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    ID-LVA Group

    Immediate distal lymphaticovenous anastomosis (ID-LVA) performed concomitantly with axillary lymph node dissection (ALND)

    Procedure: Immediate Distal Lymphaticovenous Anastomosis (ID-LVA)

  • No intervention
    non-ID-LVA Group

    Axillary lymph node dissection (ALND) without concurrent immediate distal lymphaticovenous anastomosis (ID-LVA)

Interventions

  • ProcedureImmediate Distal Lymphaticovenous Anastomosis (ID-LVA)

    ID-LVA (Immediate Distal Lymphaticovenous Anastomosis) is an supermicrosurgical technique performed during axillary lymph node dissection (ALND) to prevent breast cancer-related lymphedema, offering the dual advantages of immediate intervention and radiation-field avoidance. Compared to LYMPHA (Lymphatic Microsurgical Preventive Healing Approach), which utilizes proximal axillary anastomoses within the radiation field with larger vessels and higher venous pressure, ID-LVA creates precise anastomoses between 0.3-0.8mm distal superficial lymphatic vessels and low-pressure venules in the upper arm. In contrast to DD-LVA (Delayed Distal Lymphaticovenous Anastomosis) performed postoperatively (typically 4-12 weeks after ALND) for subclinical lymphedema, ID-LVA provides earlier prevention by utilizing undamaged lymphatics and avoids the need for a second procedure.

    Also known as: Supermicrosurgical Lymphaticovenous Anastomosis

06

What researchers measure

Primary outcomes

  1. Lymphedema incidence

    Breast cancer-related lymphedema (BCRL) was assessed using relative volume change (RVC) derived from circumferential measurements of both upper limbs. Certified lymphedema therapists performed standardized measurements at anatomical landmarks: the web space, ulnar styloid midpoint, and points 10, 20, 30, and 40 cm above the ulnar styloid; axillary measurements were added if needed. Segmental volumes were calculated using the truncated cone formula: V = (πh/12) × (C₁² + C₁C₂ + C₂²), where h = 10 cm, and C₁, C₂ are circumferences at segment ends. Total arm volume was the sum of all segments. RVC was computed as: RVC = (A₂U₁) / (A₁U₂) × 100%, where A₁/A₂ = pre-/postoperative volume of the affected arm, and U₁/U₂ = pre-/postoperative volume of the unaffected arm. If weight fluctuated significantly, weight-adjusted change (WAC) was calculated: WAC = (A₂ × W₁) / (W₂ × A₁) - 1, where W₁ and W₂ represent the preoperative and postoperative body weight.

    Time frame: From enrollment to 24 months after surgery

Secondary outcomes

  1. Lymphedema Severity

    The severity of lymphedema is classified into stages 0 to Ⅲ by breast surgeons and lymphedema therapists according to the International Society of Lymphology (ISL) staging system.

    Time frame: From enrollment to 24 months after surgery

  2. Lymphedema-Associated Symptoms

    Upper limb lymphedema symptoms were assessed using a patient self-reported format. The Breast Cancer and Lymphedema Symptom Experience Index (BCLE-SEI), developed by Fu et al., was employed to evaluate patients' experiences of lymphedema-related symptoms. The scale consists of two components: symptom occurrence and symptom distress. In this study, only the symptom occurrence component was used, which includes 24 items. Each item is rated on a 5-point Likert scale (0 = not at all to 4 = very much), yielding a total score ranging from 0 to 96. Higher scores indicate more severe symptoms. Additionally, each item can be treated as a categorical variable based on the presence or absence of the symptom. The Cronbach's alpha coefficient for this scale is 0.930.

    Time frame: From enrollment to 24 months after surgery

  3. Quality of Life (QoL)

    Quality of life was evaluated using the Functional Assessment of Cancer Therapy - Breast (FACT-B), a validated patient-reported outcome measure developed by David Cella and colleagues as part of the Functional Assessment of Chronic Illness Therapy (FACIT) system, under the Center on Outcomes, Research and Education (CORE) at Northwestern University, United States. The FACT-B consists of 36 items across five domains: physical well-being, social/family well-being, emotional well-being, functional well-being, and additional concerns. Each item is rated on a 4-point Likert scale (0 = not at all to 4 = very much), with higher scores indicating better quality of life. The Chinese version was translated and culturally adapted by Wan Chonghua et al., with reported Cronbach's alpha coefficients ranging from 0.61 to 0.84.

    Time frame: From enrollment to 24 months after surgery

  4. Surgery-Related Complications

    Time frame: From the day of surgery to 1 month after surgery

  5. Radiation-Related Complications

    Time frame: From the day of radiation to 7 days after radiation

  6. Disease-Free Survival (DFS)

    Time frame: From enrollment to 24 months after surgery

  7. Local Recurrence-Free Survival (LRFS)

    Time frame: From enrollment to 24 months after surgery

  8. Overall Survival (OS)

    Time frame: From enrollment to 24 months after surgery

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — All IPD collected throughout the trial, only IPD used in the results publication.

Supporting information: Study protocol

Time frame: From June 1, 2025 to May 31, 2029.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2025; primary completion for May 2027, 22 months later.

Of 66 non-industry interventional studies with no phase under Breast Cancer Lymphedema, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 34. This study's planned 22 months is above that.

Counting every sponsor, half of 69 studies reached it within 18 months; a quarter within 10 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2025
First posted
Jun 18, 2025
StartEst.
Jul 1, 2025
Primary completionEst.
May 31, 2027
CompletionEst.
May 31, 2029
Last update
Jun 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07026292
Responsible party
Sponsor
First posted
Jun 18, 2025
Start date
Jul 1, 2025 (estimated)
Primary completion
May 31, 2027 (estimated)
Completion
May 31, 2029 (estimated)
Last update
Jun 18, 2025

Study contacts

Hongmeng Zhao
Contact
zhaohongmeng@tjmuch.com
+86 22 6515 0123 ext. 8500/8520

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion